Advanced Biological Laboratories

Medical technology and diagnostics software provider

Advanced Biological Laboratories

Medical technology and diagnostics software provider

Overview

ABL develops software, assays, and IT solutions for infectious disease diagnostics. Its products, such as DeepChek®, ViroScore®, and UltraGene®, support drug-resistance analysis, genotyping, and DNA/RNA quantification, compatible with Sanger sequencing and high-throughput NGS. The company sells end-to-end solutions to academic labs, reference laboratories, and researchers, combining molecular detection, sequencing, data analysis, and CRO/assay manufacturing services through acquisitions to generate recurring revenue. By integrating software, wet-lab assays, and EMR assets, ABL aims to streamline infectious disease testing and data-driven clinical decisions.

Work here?Claim your company

About Advanced Biological Laboratories

Simplify's Rating

Why Advanced Biological Laboratories is rated

C+

Rated B on Competitive Edge

Rated B on Growth Potential

Rated D+ on Differentiation

Industries

Data & AnalyticsEnterprise SoftwareBiotechnologyHealthcare

Company Size

N/A

Company Stage

IPO

Headquarters

Luxembourg, Luxembourg

Founded

2000

Simplify's take

What believers are saying

ABL Diagnostics reported 2025 revenue €6.95 million and net income €0.987 million.
July 2026 launched UltraGene Viral Meningitis, broadening syndromic PCR distribution worldwide.
June 2026 roadmap targets €12.265 million revenue for 2026, up 76.5%.

What critics are saying

IVDR deadlines hit 2028-2029; missed certificates can freeze legacy assay sales.
The cancelled ProPhase reverse merger on February 19, 2026 showed M&A execution fragility.
Small-caps cash stays tight: June 2026 cash fell to €853k versus €1.31m.

What makes Advanced Biological Laboratories unique

ABL owns CE-IVD molecular assays, sequencing software, and OpenChek automation.
July 2026 BSI IVDR roadmap protects DeepChek, ViroScore, and UltraGene commercialization.
ABL integrates acquired assets from Siemens Healthineers, Texcell, Humedics, and CDL Pharma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours
Professional Development Budget

Company News

FinanzNachrichten.de

Jul 28th, 2026

ABL Diagnostics Announces Amendment to the Equity Line and Share Loan Agreement Between Its Main Shareholder ABL SA (Luxembourg) and Alumni Capital

Introduction of a minimum floor price of €4.50 per share for any future drawdown Reduction of the maximum drawdown size from 50,000 to 2,500 shares Immediate return of 98,026 loaned

Associated Press

Jul 28th, 2026

ABL Diagnostics launches UltraGene Viral Meningitis PCR assay with CE-IVD registration

ABL Diagnostics has announced the commercial availability of UltraGene Viral Meningitis, a multiplex real-time PCR assay for detecting viral pathogens associated with meningitis and central nervous system infections. The test can identify six viruses from cerebrospinal fluid specimens, including HSV-1, HSV-2, and Enterovirus. The product originates from the former Fast Track Diagnostics portfolio, which ABL acquired from Siemens Healthineers in 2025. It has obtained CE-IVD registration under Council Directive 98/79/EC through ABL SA Luxembourg. The assay can be automated on ABL Diagnostics' OpenChek platform, enabling laboratories to streamline sample processing. ABL Diagnostics will handle worldwide commercialisation and distribution, with availability across Europe, the Middle East, Africa, Asia, and Latin America. The company is working towards compliance with the European IVDR regulatory framework as part of its long-term strategy.

EIN News

Apr 15th, 2026

ABL S.A. secures new private investor to strengthen life-sciences platform

Advanced Biological Laboratories (ABL) S.A., a Luxembourg-based medtech and biotechnology company, has announced the entry of a new private investor through a minority shareholding acquisition. Existing shareholders retain control, with governance arrangements unchanged. ABL Luxembourg serves as parent company to Euronext-listed ABL Diagnostics and operates as an active technological platform with expertise in healthcare information systems and sequencing data analysis. The company has distributed dividends regularly since 2021. The group's subsidiaries include CDL Pharma, which recently consolidated pharmaceutical activities, and Humedics, focused on biomedical research. ABL announced in 2025 the acquisition of Fast Track Diagnostics' intangible assets. The company has also entered preliminary discussions regarding potential US market entry, though no definitive agreement has been reached.

ProPhase Labs, Inc.

Dec 22nd, 2025

ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company.

EIN Presswire

Oct 22nd, 2025

ABL Luxembourg Announces Second Strategic Agreement with Alumni Capital to Support ABL Diagnostics’ Growth

Advanced Biological Laboratories S.A. (“ABL Luxembourg”) is pleased to announce the signing of a new share purchase agreement with Alumni Capital, a U.S.-based

Recently Posted Jobs